In Clinical news

Follow this topic

Bookmark

Record learning outcomes

The MHRA has granted UK marketing authorisation for EURneffy (adrenaline 2mg) from pharmaceutical company ALK, claimed to be the first ready-to-use, needle-free intranasal spray for emergency treatment of anaphylaxis in adults and children weighing ≥30kg.

The new device offers a non-invasive alternative to traditional auto-injectors, with clinical outcomes shown to be comparable across a range of dosing conditions — including in patients with allergic rhinitis and nasal congestion. 

Studies presented at the recent EAACI Congress in Glasgow demonstrated that the spray produced adrenaline levels and cardiovascular responses similar or superior to 0.3mg adrenaline intramuscular injection, even in congested patients.

The compact device (5.7cm x 4.5cm x 1.9cm) fits easily in a pocket, has a 30-month shelf-life, requires no refrigeration and needs no priming, says ALK. With data suggesting that up to half of patients with severe allergies do not carry or use their prescribed auto-injectors, EURneffy could help overcome hesitation in emergency situations, it adds.

Also read: Allergy or infection? You decide